High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India

D'souza, Desiree T. B.; Mistry, Nerges F.; Vira, Tina S.; Dholakia, Yatin; Hoffner, Sven; Pasvol, Geoffrey; Nicol, Mark; Wilkinson, Robert J.
January 2009
BMC Public Health;2009, Vol. 9 Issue 1, p211
Academic Journal
Background: India, China and Russia account for more than 62% of multidrug resistant tuberculosis (MDRTB) globally. Within India, locations like urban metropolitan Mumbai with its burgeoning population and high incidence of TB are suspected to be a focus for MDRTB. However apart from sporadic surveys at watched sites in the country, there has been no systematic attempt by the Revised National Tuberculosis Control Programme (RNTCP) of India to determine the extent of MDRTB in Mumbai that could feed into national estimates. Drug susceptibility testing (DST) is not routinely performed as a part of programme policy and public health laboratory infrastructure, is limited and poorly equipped to cope with large scale testing. Methods: From April 2004 to January 2007 we determined the extent of drug resistance in 724 {493 newly diagnosed, previously untreated and 231 first line treatment failures (sputum-smear positive at the fifth month after commencement of therapy)} cases of pulmonary tuberculosis drawn from the RNTCP in four suboptimally performing municipal wards of Mumbai. The observations were obtained using a modified radiorespirometric Buddemeyer assay and validated by the Swedish Institute for Infectious Disease Control, Stockholm, a supranational reference laboratory. Data was analyzed utilizing SPSS 10.0 and Epi Info 2002. Results: This study undertaken for the first time in RNTCP outpatients in Mumbai reveals a high proportion of MDRTB strains in both previously untreated (24%) and treatment-failure cases (41%). Amongst new cases, resistance to 3 or 4 drug combinations (amplified drug resistance) including isoniazid (H) and rifampicin (R), was greater (20%) than resistance to H and R alone (4%) at any point in time during the study. The trend for monoresistance was similar in both groups remaining highest to H and lowest to R. External quality control revealed good agreement for H and R resistance (k = 0.77 and 0.76 respectively). Conclusion: Levels of MDRTB are much higher in both previously untreated and first line treatment-failure cases in the selected wards in Mumbai than those projected by national estimates. The finding of amplified drug resistance suggests the presence of a well entrenched MDRTB scenario. This study suggests that a wider set of surveillance sites are needed to obtain a more realistic view of the true MDRTB rates throughout the country. This would assist in the planning of an adequate response to the diagnosis and care of MDRTB.


Related Articles

  • Multidrug-Resistant Tuberculosis, Somalia, 2010-2011. Sindani, Ireneaus; Fitzpatrick, Christopher; Falzon, Dennis; Suleiman, Bashir; Arube, Peter; Adam, Ismail; Baghdadi, Samiha; Bassili, Amal; Zignol, Matteo // Emerging Infectious Diseases;Mar2013, Vol. 19 Issue 3, p478 

    In a nationwide survey in 2011, multidrug-resistant tuberculosis (MDR TB) was found in 5.2% and 40.8% of patients with new and previously treated TB, respectively. These levels of drug resistance are among the highest ever documented in Africa and the Middle East. This finding presents a serious...

  • Multidrug and Extensively Drug-resistant Tuberculosis in Canada 1997-2008: Demographic and Disease Characteristics. Minion, Jessica; Gallant, Victor; Wolfe, Joyce; Jamieson, Frances; Long, Richard // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Setting: Nationwide Canadian public health surveillance. Objective: Description of demographic features and disease characteristics of drug-resistant tuberculosis (TB) in Canada over a 12 year period. Design: Continuous surveillance of all cases of culture-confirmed TB in Canada. Demographic and...

  • High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009-2010. Sanchez-Padilla, Elisabeth; Dlamini, Themba; Ascorra, Alexandra; Rüsch-Gerdes, Sabine; Tefera, Zerihun Demissie; Calain, Philippe; de la Tour, Roberto; Jochims; Richter, Elvira; Bonnet, Maryline // Emerging Infectious Diseases;Jan2012, Vol. 18 Issue 1, p29 

    In Africa, although emergence of multidrug-resistant (MDR) tuberculosis (TB) represents a serious threat in countries severely affected by the HIV epidemic, most countries lack drug-resistant TB data. This finding was particularly true in the Kingdom of Swaziland, which has the world's highest...

  • Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa. Klopper, Marisa; Warren, Robin Mark; Hayes, Cindy; van Pittius, Nicolaas Claudius Gey; Streicher, Elizabeth Maria; Müller, Borna; Sirgel, Frederick Adriaan; Chabula-Nxiweni, Mamisa; Hoosain, Ebrahim; Coetzee, Gerrit; van Helden, Paul David; Victor, Thomas Calldo; Trollip, André Phillip // Emerging Infectious Diseases;Mar2013, Vol. 19 Issue 3, p449 

    Factors driving the increase in drug-resistant tuberculosis (TB) in the Eastern Cape Province, South Africa, are not understood. A convenience sample of 309 drug-susceptible and 342 multidrug-resistant (MDR) TB isolates, collected July 2008-July 2009, were characterized by spoligotyping, DNA...

  • Drug-resistant TB poses a higher risk to people in prison.  // Nursing Standard;5/5/2010, Vol. 24 Issue 35, p17 

    The article discusses research which found that prisoners were at a higher risk for developing drug-resistant tuberculosis (TB) than their non-incarcerated counterparts.

  • Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment. Xu, Hong-Bin; Jiang, Rui-Hua; Tang, Shen-Jie; Li, Ling; Xiao, He-Ping // Journal of Antimicrobial Chemotherapy (JAC);Mar2014, Vol. 69 Issue 3, pe1 

    The article presents the notice of retraction for the study "Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment," by Hong-Bin Xu and colleagues.

  • Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar. TRIPATHY, SUNITA; KUMAR, RAJESH; SINGH, SURYA DEO // Journal of Clinical & Diagnostic Research;Nov2015, Vol. 9 Issue 11, p9 

    Introduction: Multidrug resistant tuberculosis (MDR-TB) is caused by Infection with Mycobacterium tuberculosis which is resistant to both isoniazid (INH) and rifampicin (RIF), with or without any other anti tubercular drug. It is caused by resistant mutant strains due to inadequate treatment and...

  • Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance. Mitchell, S. L.; Seoudi, N.; Hutchison, D. C. S.; Drobniewski, F. A. // Thorax;Jul2011, Vol. 66 Issue 7, p630 

    A letter to the editor is presented regarding a study which investigated the resistance rates and the role played by rapid molecular testing in multidrug-resistant tuberculosis (MDRTB) patients in Great Britain from January 2008 and December 2009.

  • Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications. Ramachandran, Geetha; Swaminathan, Soumya // Drug Safety;Mar2015, Vol. 38 Issue 3, p253 

    Tuberculosis (TB) remains a major public health problem, representing the second leading cause of death from infectious diseases globally, despite being nearly 100 % curable. Multidrug-resistant (MDR)-TB, a form of TB resistant to isoniazid and rifampicin (rifampin), two of the key first-line TB...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics